Impact of structural modifications of IgG antibodies on effector functions

Timon Damelang; Timon Damelang; Timon Damelang; Timon Damelang; Maximilian Brinkhaus; Maximilian Brinkhaus; Thijs L. J. van Osch; Thijs L. J. van Osch; Janine Schuurman; Aran F. Labrijn; Theo Rispens; Gestur Vidarsson; Gestur Vidarsson

doi:10.3389/fimmu.2023.1304365

Frontiers in Immunology (Jan 2024)

Impact of structural modifications of IgG antibodies on effector functions

Timon Damelang,
Timon Damelang,
Timon Damelang,
Timon Damelang,
Maximilian Brinkhaus,
Maximilian Brinkhaus,
Thijs L. J. van Osch,
Thijs L. J. van Osch,
Janine Schuurman,
Aran F. Labrijn,
Theo Rispens,
Gestur Vidarsson,
Gestur Vidarsson

Affiliations

Timon Damelang: Sanquin Research, Department of Experimental Immunohematology and Landsteiner Laboratory, Amsterdam, Netherlands
Timon Damelang: Sanquin Research, Department of Immunopathology, Amsterdam, Netherlands
Timon Damelang: Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, Netherlands
Timon Damelang: Department of Antibody Research & Technologies’, Genmab, Utrecht, Netherlands
Maximilian Brinkhaus: Sanquin Research, Department of Experimental Immunohematology and Landsteiner Laboratory, Amsterdam, Netherlands
Maximilian Brinkhaus: Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, Netherlands
Thijs L. J. van Osch: Sanquin Research, Department of Experimental Immunohematology and Landsteiner Laboratory, Amsterdam, Netherlands
Thijs L. J. van Osch: Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, Netherlands
Janine Schuurman: Department of Antibody Research & Technologies’, Genmab, Utrecht, Netherlands
Aran F. Labrijn: Department of Antibody Research & Technologies’, Genmab, Utrecht, Netherlands
Theo Rispens: Sanquin Research, Department of Immunopathology, Amsterdam, Netherlands
Gestur Vidarsson: Sanquin Research, Department of Experimental Immunohematology and Landsteiner Laboratory, Amsterdam, Netherlands
Gestur Vidarsson: Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, Netherlands

DOI: https://doi.org/10.3389/fimmu.2023.1304365
Journal volume & issue: Vol. 14

Abstract

Read online

Immunoglobulin G (IgG) antibodies are a critical component of the adaptive immune system, binding to and neutralizing pathogens and other foreign substances. Recent advances in molecular antibody biology and structural protein engineering enabled the modification of IgG antibodies to enhance their therapeutic potential. This review summarizes recent progress in both natural and engineered structural modifications of IgG antibodies, including allotypic variation, glycosylation, Fc engineering, and Fc gamma receptor binding optimization. We discuss the functional consequences of these modifications to highlight their potential for therapeutical applications.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords